Gibson Dunn Advises Jade Biosciences on Merger With Aerovate Therapeutics, Inc. and Concurrent Private Placement
November 01, 2024
November 01, 2024
LOS ANGELES, California, Nov. 1 -- Gibson, Dunn and Crutcher, a law firm, issued the following news:
Gibson Dunn is advising Jade Biosciences on its merger with Aerovate Therapeutics, Inc. and the concurrent $300 million private placement of shares of its common stock and pre-funded warrants to a syndicate of healthcare investors.
The Gibson Dunn corporate team includes partners Ryan Murr, Branden Berns and Chris Trester and associates Evan Shepherd and Candice Johnson. . . .
Gibson Dunn is advising Jade Biosciences on its merger with Aerovate Therapeutics, Inc. and the concurrent $300 million private placement of shares of its common stock and pre-funded warrants to a syndicate of healthcare investors.
The Gibson Dunn corporate team includes partners Ryan Murr, Branden Berns and Chris Trester and associates Evan Shepherd and Candice Johnson. . . .